These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 738344)

  • 41. Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy.
    Hubbard SM; Barkes P; Young RC
    Cancer Treat Rep; 1978 Sep; 62(9):1375-7. PubMed ID: 688281
    [No Abstract]   [Full Text] [Related]  

  • 42. [Chemotherapeutic treatment of advanced ovarian carcinoma. Preliminary results of the Piedmont-Liguria Cooperative Group].
    Conte PF; Rosso R; Bruzzone M; Sertoli MR; Rubagotti A; Santi L; Carnino F; Cottini M; Mossetti C; Gatti M
    Minerva Ginecol; 1984 Apr; 36(4):213-6. PubMed ID: 6547773
    [No Abstract]   [Full Text] [Related]  

  • 43. [A combination of cyclophosphamide, adriamycin and platinum (CAP) in the treatment of stage III and IV ovarian cancer].
    Chylak V; Krusić J; Kolarić K
    Jugosl Ginekol Perinatol; 1988; 28(1-2):41-3. PubMed ID: 3398564
    [No Abstract]   [Full Text] [Related]  

  • 44. Chemotherapy of ovarian cancer: past and present.
    Young RC
    Semin Oncol; 1975 Sep; 2(3):267-76. PubMed ID: 827024
    [No Abstract]   [Full Text] [Related]  

  • 45. Adriamycin-cyclophosphamide and adriamycin-cis-dichloro-diammineplatinum(II) combination chemotherapy in patients with advanced cancer.
    Higby DJ; Wilbur D; Wallace HJ; Henderson ES; Weiss R
    Cancer Treat Rep; 1977 Aug; 61(5):869-73. PubMed ID: 329980
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemotherapy of bladder carcinoma with cyclophosphamide and adriamycin.
    Merrin C; Cartagena R; Wajsman Z; Baumgartner G; Murphy GP
    J Urol; 1975 Dec; 114(6):884-7. PubMed ID: 1195468
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5.
    Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Vriesendorp R; Pinedo HM
    Radiother Oncol; 1984 Jun; 2(1):19-29. PubMed ID: 6438704
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination therapy with adriamycin, cyclophosphamide and vicristine for advanced breast cancer supplemented with non cross-resistant combination.
    Jain SP; Pandey UC; Tandon US; Jain KK; Agarwal S
    Indian J Cancer; 1979; 16(3-4):43-6. PubMed ID: 540959
    [No Abstract]   [Full Text] [Related]  

  • 49. Melphalan vs polymelphalanum in ovarian cancer patients resistant to cyclophosphamide: a tentative statistical approach to balance risks and benefits.
    Morasca L; Recchia M; Gramellini E; Bolis G; Mangioni C
    Eur J Cancer (1965); 1977 Aug; 13(8):817-20. PubMed ID: 908343
    [No Abstract]   [Full Text] [Related]  

  • 50. Bypassing multidrug resistant ovarian cancer using ultrasound responsive doxorubicin/curcumin co-deliver alginate nanodroplets.
    Baghbani F; Moztarzadeh F
    Colloids Surf B Biointerfaces; 2017 May; 153():132-140. PubMed ID: 28235723
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Experience with adriamycin in the treatment of advanced breast and ovarian cancer (author's transl)].
    Kolarić K; Maricić Z ; Krusić J; Nola P
    Lijec Vjesn; 1976 Jun; 98(6):313-16. PubMed ID: 790065
    [No Abstract]   [Full Text] [Related]  

  • 52. Advanced ovarian carcinoma: a pilot study of cis-dichlorodiammineplatinum(II) in combination with adriamycin and cyclophosphamide in previously untreated patients and as a single agent in previously treated patients.
    Williams CJ; Stevenson KE; Buchanan RB; Whitehouse JM
    Cancer Treat Rep; 1979; 63(11-12):1745-53. PubMed ID: 393378
    [No Abstract]   [Full Text] [Related]  

  • 53. Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines.
    Harstrick A; Schmoll HJ; Sass G; Poliwoda H; Rustum Y
    Eur J Cancer; 1993; 29A(7):1000-2. PubMed ID: 8499130
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Status report of Mayo Clinic studies.
    Edmonson JH
    Natl Cancer Inst Monogr; 1975 Oct; 42():167-8. PubMed ID: 1243994
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Complete remission at laparotomy: still a gold standard in ovarian cancer?
    Neijt JP; ten Bokkel Huinink WW; Van der Burg ME; van Oosterom AT
    Lancet; 1986 May; 1(8488):1028. PubMed ID: 2871299
    [No Abstract]   [Full Text] [Related]  

  • 56. Combination chemotherapy with mitomycin C, adriamycin, and cyclophosphamide (MAC) in stage III and IV ovarian cancer.
    Ratanatharathorn V; Samson MK; Baker LH; Pollard R; Cummings G; Fraile RJ
    Am J Clin Oncol; 1983 Oct; 6(5):565-70. PubMed ID: 6412538
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report.
    Ehrlich CE; Einhorn L; Williams SD; Morgan J
    Cancer Treat Rep; 1979 Feb; 63(2):281-8. PubMed ID: 376134
    [No Abstract]   [Full Text] [Related]  

  • 58. [Platinum in tumor therapy].
    MMW Munch Med Wochenschr; 1979 Jan; 121(4):119. PubMed ID: 104154
    [No Abstract]   [Full Text] [Related]  

  • 59. A newly developed in vitro chemosensitivity test (nuclear damage assay): application to ovarian cancer.
    Sekiya S; Iijima N; Oosaki T; Takamizawa H; Tokita H
    Gynecol Oncol; 1991 Feb; 40(2):138-43. PubMed ID: 2010105
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas.
    Edmonson JH; McCormack GW; Fleming TR; Cullinan SA; Krook JE; Malkasian GD; Podratz KC; Mailliard JA; Jefferies JA; Barlow JF
    Cancer Treat Rep; 1985 Nov; 69(11):1243-8. PubMed ID: 3937598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.